Calla positive lymphocytic leukemia, also known as CAL+LL, is a specific type of leukemia characterized by the presence of a cell surface antigen called CD10 or common acute lymphoblastic leukemia antigen (CALLA). Leukemia is a cancer of the blood and bone marrow that affects the production of normal blood cells, leading to an excessive proliferation of immature white blood cells.
In CAL+LL, lymphoid cells, specifically B-lymphocytes, become abnormal and grow uncontrollably, crowding out healthy cells in the bone marrow and impairing the production of other necessary blood cells, such as red blood cells and platelets. The presence of the CD10 antigen on these abnormal cells is useful in the diagnosis and classification of this type of leukemia.
Symptoms of CAL+LL may include fatigue, weakness, anemia, frequent infections, easy bruising or bleeding, enlarged lymph nodes, and weight loss. Diagnosis is typically made through blood tests, bone marrow aspiration, and biopsy.
Treatment for CAL+LL often involves a combination of chemotherapy, targeted therapy, and sometimes stem cell transplantation, depending on the individual patient's characteristics and response to treatment. Prognosis varies depending on factors such as age, overall health, response to treatment, and the presence of specific genetic abnormalities associated with the disease.
Overall, CAL+LL is a specific subtype of leukemia characterized by the presence of the CD10 antigen, which can be diagnosed through various medical tests and requires treatment tailored to the individual case for the best possible outcome.
